

CITATION REPORT

List of articles citing

HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant

DOI: 10.1053/j.gastro.2016.07.012
Gastroenterology, 2016, 151, 986-998.e4.

Source: <https://exaly.com/paper-pdf/64607688/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
281	The Concept of Immune Tolerance in Chronic Hepatitis B Virus Infection Is Alive and Well. <i>Gastroenterology</i> , 2016 , 151, 801-804	13.3	18
280	"To Be or Not to Be": Immune Tolerance in Chronic Hepatitis B. <i>Gastroenterology</i> , 2016 , 151, 805-806	13.3	13
279	Viral hepatitis: 'Immune tolerance' in HBV infection: danger lurks. 2016 , 13, 627-628		4
278	Immune Tolerance Phase of Chronic Hepatitis B. <i>Gastroenterology</i> , 2017 , 152, 1245-1246	13.3	5
277	Reply. <i>Gastroenterology</i> , 2017 , 152, 1246-1247	13.3	
276	Novel viral and host targets to cure hepatitis B. 2017 , 24, 38-45		16
275	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017 , 67, 370-398	13.4	2354
274	Chronic viral hepatitis and its association with liver cancer. 2017 , 398, 817-837		55
273	Smaller reduction of hepatitis B virus DNA in liver tissue than in serum in patients losing HBeAg. 2017 , 89, 1937-1943		5
272	Therapeutic vaccination for chronic hepatitis B. 2017 , 23, 75-81		44
271	Current therapeutic approaches for HBV infected patients. <i>Journal of Hepatology</i> , 2017 , 67, 412-414	13.4	8
270	Peripartum cytokine flares in a multiethnic cohort of chronic hepatitis B carriers does not correlate with hepatitis B virus suppression or increased risk of liver disease. 2017 , 78, e12707		7
269	Clinical Trial Design for Immune-Based Therapy of Hepatitis B Virus. <i>Seminars in Liver Disease</i> , 2017 , 37, 85-94	7.3	6
268	Management of Chronic Hepatitis B in Children. 2017 , 16, 81-89		
267	Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT \geq ULN: A retrospective cohort study. 2017 , 96, e6336		22
266	Elimination of Hepatitis B: Is It a Mission Possible?. 2017 , 15, 53		19
265	HBV in 2016: Global and immunotherapeutic insights into hepatitis B. 2017 , 14, 71-72		12

264	Detection of Hepatocyte Clones Containing Integrated Hepatitis B Virus DNA Using Inverse Nested PCR. 2017 , 1540, 97-118		9
263	Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. 2017 , 216, 1407-1414		23
262	T-cell therapy for chronic viral hepatitis. 2017 , 19, 1317-1324		18
261	Challenges to a Cure for HBV Infection. <i>Seminars in Liver Disease</i> , 2017 , 37, 231-242	7.3	19
260	Deciphering the Origin and Evolution of Hepatitis B Viruses by Means of a Family of Non-enveloped Fish Viruses. 2017 , 22, 387-399.e6		90
259	Viral hepatitis and liver cancer. 2017 , 372,		153
258	How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?. <i>Journal of Hepatology</i> , 2017 , 67, 1281-1297	13.4	81
257	Hepatitis B cure: From discovery to regulatory approval. <i>Journal of Hepatology</i> , 2017 , 67, 847-861	13.4	123
256	Hepatitis B cure: From discovery to regulatory approval. <i>Hepatology</i> , 2017 , 66, 1296-1313	11.2	150
255	Tolerance and immunity to pathogens in early life: insights from HBV infection. 2017 , 39, 643-652		31
254	Reply to: "Serum HBV pgRNA as a clinical marker for cccDNA activity": Consistent loss of serum HBV RNA might predict the "para-functional cure" of chronic hepatitis B. <i>Journal of Hepatology</i> , 2017 , 66, 462-463	13.4	30
253	Stop codons in the hepatitis B surface proteins are enriched during antiviral therapy and are associated with host cell apoptosis. 2017 , 501, 70-78		9
252	Hepatitis B and D. 2017 , 584-627		
251	Human immunodeficiency virus and liver disease: A comprehensive update. <i>Hepatology Communications</i> , 2017 , 1, 987-1001	6	14
250	Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs. 2017 , 11, 502-508		21
249	The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease. 2017 , 8, 28641-28649		16
248	Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application. <i>Viruses</i> , 2017 , 9,	6.2	138
247	HBV DNA Integration: Molecular Mechanisms and Clinical Implications. <i>Viruses</i> , 2017 , 9,	6.2	175

246	Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks. <i>Viruses</i> , 2017 , 9,	6.2	35
245	A Role for the Host DNA Damage Response in Hepatitis B Virus cccDNA Formation-and Beyond?. <i>Viruses</i> , 2017 , 9,	6.2	56
244	Control of viral transcripts as a concept for future HBV therapies. 2018 , 30, 18-23		13
243	Impact of integrated viral DNA on the goal to clear hepatitis B surface antigen with different therapeutic strategies. 2018 , 30, 24-31		14
242	Relative Abundance of Integrant-Derived Viral RNAs in Infected Tissues Harvested from Chronic Hepatitis B Virus Carriers. 2018 , 92,		21
241	Current and future directions of management of hepatitis B: steps toward a cure. 2018 , 13, 189-209		1
240	Why, who and when to start treatment for chronic hepatitis B infection. 2018 , 30, 39-47		13
239	Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles. 2018 , 92,		81
238	Liver sampling: a vital window into HBV pathogenesis on the path to functional cure. 2018 , 67, 767-775		24
237	Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand. 2018 , 3, 192-202		46
236	Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals. 2018 , 99-100, 71-78		44
235	The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. 2018 , 244, 304-310		23
234	High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. 2018 , 67, 945-952		95
233	HBV infection and HCC: the 'dangerous liaisons'. 2018 , 67, 787-788		16
232	Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers. 2018 , 17, 232-241		3
231	Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. <i>Clinical and Molecular Hepatology</i> , 2018 , 24, 108-113	6.9	29
230	Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy?. 2018 , 3,		1
229	Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status. 2018 , 19, 561-571		13

228	The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics. 2019 , 26, 4-15		7
227	Chronic hepatitis B virus infection. 2018 , 392, 2313-2324		206
226	An Assessment of Upper Limits of Normal for ALT and the Impact on Evaluating Natural Course of Chronic Hepatitis B Virus Infection in Chinese Children. 2018 , 113, 1660-1668		4
225	Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. 2018 , 30, 68-79		32
224	Reply to: "Immunotolerant children with chronic hepatitis B - To treat or not - The dilemma continues". <i>Journal of Hepatology</i> , 2018 , 69, 981-982	13.4	1
223	Cellular Genomic Sites of Hepatitis B Virus DNA Integration. 2018 , 9,		35
222	Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients. 2018 , 25, 1161-1171		13
221	Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination. 2018 , 30, 58-67		40
220	Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B. <i>Antiviral Research</i> , 2018 , 158, 185-198	10.8	37
219	Sequence analysis of integrated hepatitis B virus DNA during HBeAg-seroconversion. 2018 , 7, 142		16
218	Integration of hepatitis B virus DNA in chronically infected patients assessed by Alu-PCR. 2018 , 90, 1568-1575		10
217	Hepatitis B virus infection. 2018 , 4, 18035		250
216	Virological Basis for the Cure of Chronic Hepatitis B. 2019 , 5, 659-674		31
215	KASL clinical practice guidelines for management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019 , 25, 93-159	6.9	87
214	Role of HBsAg Testing in the Management of Patients with Chronic HBV. 2019 , 18, 331-341		5
213	Genomic modeling of hepatitis B virus integration frequency in the human genome. 2019 , 14, e0220376		21
212	Chronic hepatitis B virus infection drives changes in systemic immune activation profile in patients coinfecting with Plasmodium vivax malaria. 2019 , 13, e0007535		10
211	Detection and Characterization of Hepatitis B Virus-Specific CD8 T Cells in Patients Considered Immune Tolerant. <i>Frontiers in Immunology</i> , 2019 , 10, 1319	8.4	9

210	Hepatitis B virus infection in children and adolescents. 2019 , 4, 466-476	62
209	Within-host mathematical models of hepatitis B virus infection: Past, present, and future. 2019 , 18, 27-35	11
208	Updates in the management of hepatitis B in children. 2019 , 13, 1065-1076	5
207	Are the Patients in the Immune Tolerant Phase of Chronic Hepatitis B far from Hepatocellular Carcinoma or Death?. 2019 , 74, 66	
206	HBV-Induced Immune Imbalance in the Development of HCC. <i>Frontiers in Immunology</i> , 2019 , 10, 2048	8.4 71
205	Analyse chromosomaler integrierter HBV-DNA durch inverse nested PCR. 2019 , 25, 282-284	
204	Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. 2019 , 16, 662-675	54
203	Retrotransposon elements among initial sites of hepatitis B virus integration into human genome in the HepG2-NTCP cell infection model. 2019 , 235-236, 39-56	6
202	Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. 2019 , 20,	113
201	Hepatocellular Cancer Induced by Infection. 2019 , 247-259	
200	Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection. 2019 , 5, 703-712	8
199	Immune-Tolerant Hepatitis B: Maybe a Misnomer but Still Hard to Treat. <i>Hepatology</i> , 2019 , 69, 2315-2317	1.2 3
198	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. 2019 , 26, 856-865	11
197	A global scientific strategy to cure hepatitis B. 2019 , 4, 545-558	187
196	Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. 2019 , 9, 2508	10
195	Hepatitis B: Prognosis and Treatment. 2019 , 490-502	
194	Stellungnahme zum Beschlussentwurf des G-BA zur Nicht-Förderung der Gesundheitsuntersuchungs-Richtlinie (GU-RL): Screening auf Hepatitis B. 2019 , 57, 1236-1238	
193	Emerging tools in the changing landscape of chronic hepatitis B management. 2019 , 17, 943-955	2

192	Unsatisfying antiviral therapeutic effect in patients with mother-to-child transmitted chronic hepatitis B virus infection: a prospective multi-center clinical study. 2019 , 132, 2647-2656		2
191	Abnormal IL-10 levels were related to alanine aminotransferase abnormalities during postpartum in HBeAg positive women with chronic hepatitis B. 2019 , 98, e17969		1
190	Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection. <i>Gastroenterology</i> , 2019 , 156, 369-383	13.3	62
189	Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. <i>Gastroenterology</i> , 2019 , 156, 325-337	13.3	77
188	Hepatitis B assessment without hepatitis B virus DNA quantification: a prospective cohort study in Uganda. 2019 , 113, 11-17		3
187	Fine needle aspirates comprehensively sample intrahepatic immunity. 2019 , 68, 1493-1503		29
186	Presence of Precore (C)/C Promoter Mutants in Peripheral Blood Mononuclear Cells of Chronic Hepatitis B (CHB) Carriers During Pregnancy Does Not Correlate with Increased Risk of Liver Disease in 4 Years of Follow-Up. 2020 , 65, 204-214		2
185	Single Hepatocyte Hepatitis B Virus Transcriptional Landscape in HIV Coinfection. 2020 , 221, 1462-1469		12
184	Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. 2020 , 115, 406-414		7
183	Hepatitis B in sub-Saharan Africa-How many patients need therapy?. 2020 , 27, 560-567		6
182	Impact of Hepatitis B Virus Genetic Variation, Integration, and Lymphtropism in Antiviral Treatment and Oncogenesis. <i>Microorganisms</i> , 2020 , 8,	4.9	2
181	Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 913-914	6.1	1
180	cccDNA Maintenance in Chronic Hepatitis B - Targeting the Matrix of Viral Replication. 2020 , 13, 3873-3886		8
179	A novel target enrichment strategy in next-generation sequencing through 7-deaza-dGTP-resistant enzymatic digestion. 2020 , 13, 445		
178	Chronic hepatitis B in children, report of a single-centre longitudinal study on 152 children. 2020 , 27, 1344-1351		3
177	Abundance of non-circular intrahepatic hepatitis B virus DNA may reflect frequent integration into human DNA in chronically infected patients. 2020 ,		7
176	Chronic Hepatitis B Infection Is Associated with Increased Molecular Degree of Inflammatory Perturbation in Peripheral Blood. <i>Viruses</i> , 2020 , 12,	6.2	3
175	Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 911-912	6.1	1

174	HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B. 2020 , 27, 1061-1070		4
173	. 2020 ,		0
172	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 196-204	6.1	16
171	Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis. 2020 , 69, 1907-1912		6
170	HBV-specific CD8 T cells present higher TNF- α expression but lower cytotoxicity in hepatocellular carcinoma. 2020 , 201, 289-296		1
169	Editorial: Strategies and barriers for hepatitis B cure: implications for HIV. 2020 , 15, 151-156		
168	Infection by Hepatitis Delta Virus. <i>Viruses</i> , 2020 , 12,	6.2	9
167	HBV induced hepatocellular carcinoma and related potential immunotherapy. 2020 , 159, 104992		19
166	Epigenetic modulation in chronic hepatitis B virus infection. 2020 , 42, 173-185		26
165	Editorial: risk assessment for chronic hepatitis B patients in the immune tolerant phase-both definition and selection matter. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 213-214	6.1	
164	ULBP1 Is Elevated in Human Hepatocellular Carcinoma and Predicts Outcome. 2020 , 10, 971		5
163	Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies. 2020 , 9,		3
162	The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation. 2020 , 6, 53		26
161	Hepatitis B Virus RNA Profiles in Liver Biopsies by Digital Polymerase Chain Reaction. <i>Hepatology Communications</i> , 2020 , 4, 973-982	6	4
160	Strategies to eliminate HBV infection: an update. 2020 , 15, 35-51		4
159	Noninvasive chimeric DNA profiling identifies tumor-originated HBV integrants contributing to viral antigen expression in liver cancer. 2020 , 14, 326-337		7
158	CON: All Patients With Immune-Tolerated Hepatitis B Virus Do Not Need to Be Treated. 2020 , 15, 25-30		2
157	PRO: Patients With Chronic Hepatitis B in Immune-Tolerant Phase Should Be Treated. 2020 , 15, 21-24		0

156	Kinetics of DNA damage repair response accompanying initial hepadnavirus-host genomic integration in woodchuck hepatitis virus infection of hepatocyte. 2020 , 244, 1-10		3
155	Early treatment of chronic hepatitis B in children: Everything [to] play for?. <i>Journal of Hepatology</i> , 2020 , 72, 802-803	13.4	1
154	Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma?. <i>Gastroenterology</i> , 2020 , 158, 2028-2032	13.3	2
153	Clinical Implications of the Molecular Biology of Hepatitis B Virus. 2020 , 851-867		
152	Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. 2020 , 11, e00140		9
151	Reasons to consider early treatment in chronic hepatitis B patients. <i>Antiviral Research</i> , 2020 , 177, 104783	10.8	11
150	Oncogenic HBV variants and integration are present in hepatic and lymphoid cells derived from chronic HBV patients. 2020 , 480, 39-47		7
149	Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription. 2020 , 69, 2016-2024		53
148	Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1169-1179	6.1	19
147	Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. 2020 , 20, 480-490		36
146	Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection. <i>Gastroenterology</i> , 2020 , 159, 652-664	13.3	38
145	Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections. 2021 , 223, 128-138		3
144	Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma. <i>Hepatology</i> , 2021 , 73 Suppl 1, 27-37	11.2	7
143	Estimating hepatitis B virus cccDNA persistence in chronic infection. 2021 , 7, veaa063		8
142	Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity. <i>Journal of Hepatology</i> , 2021 , 74, 794-800	13.4	11
141	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. 2021 , 84, 68-73		1
140	synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA. <i>JHEP Reports</i> , 2021 , 3, 100195	10.3	15
139	Pharmacotherapy options for managing hepatitis B in children. 2021 , 22, 449-467		0

138	HBsAg-specific CD8 T cells as an indispensable trigger to induce murine hepatocellular carcinoma. 2021 , 18, 128-137		6
137	DeepHBV: A deep learning model to predict hepatitis B virus (HBV) integration sites.		
136	Hepatitis B Virus DNA Integration and Clonal Expansion of Hepatocytes in the Chronically Infected Liver. <i>Viruses</i> , 2021 , 13,	6.2	8
135	A novel HBsAg-based model for predicting significant liver fibrosis among Chinese patients with immune-tolerant phase chronic hepatitis B: a multicenter retrospective study. 2021 , 14, 17562848211010675		1
134	Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. 2021 ,		29
133	HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. <i>Viruses</i> , 2021 , 13,	6.2	9
132	Liver damage favors the eliminations of HBV integration and clonal hepatocytes in chronic hepatitis B. 2021 , 15, 60-70		0
131	Assessing efficacy of hepatocellular carcinoma prediction scores to prioritise hepatitis B surveillance in the COVID-19 era. 2021 , 3, 80-87		1
130	Chronic hepatitis B: the demise of the 'inactive carrier' phase. 2021 , 15, 290-300		9
129	Identification of key genes in hepatitis B associated hepatocellular carcinoma based on WGCNA. 2021 , 16, 18		4
128	Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021 , 27, 295-304	6.9	3
127	Resolved Hepatitis B: Achieved or Imaginary Wellbeing?. 2021 , 31, 7-19		
126	HBV Integration Induces Complex Interactions between Host and Viral Genomic Functions at the Insertion Site. 2021 , 9, 399-408		3
125	Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance. <i>Cancers</i> , 2021 , 13,	6.6	5
124	No evidence of human genome integration of SARS-CoV-2 found by long-read DNA sequencing.		2
123	Immunobiology and pathogenesis of hepatitis B virus infection. 2021 ,		41
122	Hepatocellular Carcinoma in Sub-Saharan Africa. 2021 , 7, 756-766		2
121	Pathogens and Carcinogenesis: A Review. 2021 , 10,		7

120	Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer. 2021 , 13, 509-535		3
119	A Non-invasive Model for Predicting Liver Inflammation in Chronic Hepatitis B Patients With Normal Serum Alanine Aminotransferase Levels. <i>Frontiers in Medicine</i> , 2021 , 8, 688091	4.9	1
118	Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps. 2021 , 8, 89-96		0
117	Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. 2021 ,		3
116	Hepatitis B virus - an anaerobic organism?. <i>Journal of Hepatology</i> , 2021 , 75, 16-18	13.4	
115	Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. 2021 , 2, 450-467		1
114	Animal Models for the Study of Hepatitis B Virus Pathobiology and Immunity: Past, Present, and Future. 2021 , 12, 715450		3
113	DeepHBV: a deep learning model to predict hepatitis B virus (HBV) integration sites. 2021 , 21, 138		1
112	Current situation of viral hepatitis in Egypt. 2021 , 65, 352-372		7
111	Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia.. 2022 , 12, 144-154		1
110	No evidence of human genome integration of SARS-CoV-2 found by long-read DNA sequencing. 2021 , 36, 109530		16
109	Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1. 2021 , 22,		0
108	Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. <i>Microorganisms</i> , 2021 , 9,	4.9	2
107	Increased hepatitis B virus quasispecies diversity is correlated with liver fibrosis progression. 2021 , 93, 104938		0
106	Targeted Long-Read Sequencing Reveals Comprehensive Architecture, Burden, and Transcriptional Signatures from Hepatitis B Virus-Associated Integrations and Translocations in Hepatocellular Carcinoma Cell Lines. 2021 , 95, e0029921		6
105	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. 2021 ,		1
104	Modeling reveals no direct role of the extent of HBV DNA integrations on the outcome of infection. 2021 , 526, 110793		
103	Quantitative serum HBV markers in predicting phases of natural history of chronic HBV infection. 2021 , 296, 114226		2

102	Hepatitis B in Children-The Pursuit of a Hepatitis Free Future Generation. 2021 , 237, 9-11		0
101	Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load. <i>Journal of Hepatology</i> , 2021 , 75, 840-847	13.4	13
100	Secondary prevention of hepatitis B virus-related hepatocellular carcinoma with current antiviral therapies. 2021 , 37, 262-267		2
99	Old hepatitis B virus never dies: It just hides itself within the host genome. <i>Clinical and Molecular Hepatology</i> , 2021 , 27, 107-109	6.9	2
98	Nucleos(t)ide Therapy and Long-Term Outcomes. 2021 , 287-318		
97	Unmet Needs in Clinical Research Hepatitis B. 2021 , 51-71		
96	Viral quasispecies quantitative analysis: a novel approach for appraising the immune tolerant phase of chronic hepatitis B virus infection. 2021 , 10, 842-851		1
95	Hepatitis B Virus DNA Integration: In Vitro Models for Investigating Viral Pathogenesis and Persistence. <i>Viruses</i> , 2021 , 13,	6.2	10
94	HBV Genome and Life Cycle. 2020 , 1179, 17-37		8
93	Immunopathogenesis of HBV Infection. 2020 , 1179, 71-107		12
92	Insights into Hepatitis B Virus DNA Integration-55 Years after Virus Discovery. 2020 , 1, 100034		15
91	Estimating hepatitis B virus cccDNA persistence in chronic infection.		2
90	Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B. 2021 , 70, 2337-2348		14
89	Network Pharmacology Approach to Explore the Potential Mechanisms of Jieduan-Niwan Formula Treating Acute-on-Chronic Liver Failure. 2020 , 2020, 1041307		4
88	Hepatitis B virus promotes E-cadherin-signalling and disassembly of adherens junctions in a Src kinase dependent fashion. 2018 , 9, 33947-33960		10
87	Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus. 2020 , 6,		4
86	Immunotherapy for Chronic Hepatitis B Virus Infection. 2018 , 12, 497-507		55
85	[Vaccination against hepatitis B as prevention for hepatocellular carcinoma]. 2021 , 1-6		

84	A River From the Liver: Detecting Hepatocyte Genomic DNA in Urine. <i>Hepatology Communications</i> , 2021 , 5, 1629-1631		6
83	T cell responses during HBV and HCV infections: similar but not quite the same?. 2021 , 51, 80-86		1
82	Progress of research on the immune tolerance of chronic HBV infection. 2018 , 7, 88-93		
81	Viral Hepatitis B. 2020 , 173-180		
80	Hepatitis B e antigen-positive chronic hepatitis B infection with minimal changes on liver biopsy: what to do next. 2020 , 156-159		
79	Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1439-1440	6.1	1
78	Efficacy of a Chinese herbal formula on hepatitis B e antigen-positive chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2020 , 26, 4501-4522	5.6	2
77	Hepatitis B Virus. 2020 , 255-272		
76	Pathological characterization of occult hepatitis B virus infection in hepatitis C virus-associated or non-alcoholic steatohepatitis-related hepatocellular carcinoma. <i>World Journal of Meta-analysis</i> , 2020 , 8, 67-77	0.5	
75	lncRNA-CD160 decreases the immunity of CD8 T cells through epigenetic mechanisms in hepatitis B virus infection. <i>Oncology Letters</i> , 2020 , 20, 235-247	2.6	5
74	Approaches to quantifying Hepatitis B Virus covalently closed circular (ccc)DNA. <i>Clinical and Molecular Hepatology</i> , 2021 ,	6.9	2
73	A Comparative Analysis of the APRI, FIB4, and FibroScan Score in Evaluating the Severity of Chronic Liver Disease in Chronic Hepatitis B Patients in India.. <i>Cureus</i> , 2021 , 13, e19342	1.2	0
72	New Direct-Acting Antiviral Agents and Immunomodulators for Hepatitis B Virus Infection. <i>Gastroenterology and Hepatology</i> , 2017 , 13, 348-356	0.7	7
71	Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	0
70	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2021 ,	19.4	57
69	Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase. <i>European Journal of Gastroenterology and Hepatology</i> , 2022 , 34, 69-75	2.2	1
68	Getting to HBV cure: the promising paths forward.. <i>Hepatology</i> , 2022 ,	11.2	3
67	Diverse facets of MDSC in different phases of chronic HBV infection: impact on HBV specific T cell response and homing.. <i>Hepatology</i> , 2022 ,	11.2	1

66	Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations with Implications on Host Gene Dysregulation.. <i>Gastroenterology</i> , 2022 ,	13.3	4
65	Hepatitis B Virus Integration into Transcriptionally Active Loci and HBV-Associated Hepatocellular Carcinoma.. <i>Microorganisms</i> , 2022 , 10,	4.9	2
64	In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma.. <i>Diagnostic Pathology</i> , 2022 , 17, 11	3	1
63	The Impact of Nucleos(t)ide Analogs on Hepatitis B Virus DNA Integration: Hype or Reality?. <i>Gastroenterology</i> , 2022 ,	13.3	
62	Viral integrations in chronic Hepatitis B infection: purposeless passenger or problematic promoter of persistence?. <i>Hepatology</i> , 2022 ,	11.2	1
61	Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B.. <i>JHEP Reports</i> , 2022 , 4, 100449	10.3	0
60	Crosstalk between Hepatitis B Virus and the 3D Genome Structure.. <i>Viruses</i> , 2022 , 14,	6.2	0
59	Innate and Adaptive Immunopathogeneses in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma.. <i>Cancers</i> , 2022 , 14,	6.6	1
58	Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B.. <i>Journal of Clinical Investigation</i> , 2022 ,	15.9	2
57	Efficient silencing of hepatitis B virus S gene through CRISPR-mediated base editing.. <i>Hepatology Communications</i> , 2022 ,	6	0
56	Making child's play of tolerance: Defining the immune-viral interplay during combination entecavir and pegylated interferon therapy for immune tolerant hepatitis B infection.. <i>Hepatology</i> , 2022 ,	11.2	
55	Changes in serum hepatitis B surface and e antigen, IP-10, and aminotransferase levels during combination therapy of immune tolerant chronic hepatitis B.. <i>Hepatology</i> , 2022 ,	11.2	0
54	KASL clinical practice guidelines for management of chronic hepatitis B.. <i>Clinical and Molecular Hepatology</i> , 2022 , 28, 276-331	6.9	2
53	Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection.. <i>JHEP Reports</i> , 2022 , 4, 100480	10.3	2
52	A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT \geq ULN.. <i>Antiviral Research</i> , 2022 , 105315	10.8	1
51	Precision medicine in the era of potent antiviral therapy for chronic hepatitis B.. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022 ,	4	0
50	Surrogate markers for hepatitis B Virus covalently closed circular DNA.. <i>Seminars in Liver Disease</i> , 2022 ,	7.3	
49	Presentation_1.pdf. 2019 ,		

48 Table_1.DOCX. **2019,**

47 Image_1.TIF. **2020,**

46 Table_1.pdf. **2020,**

45 Early Treatment Consideration in Patients with Hepatitis B B Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift?. *Viruses*, **2022**, 14, 900 6.2 0

44 Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease. *Viruses*, **2022**, 14, 1070 6.2 1

43 Chronic viral hepatitis induced liver fibrosis. **2022**, 175-192

42 Proteomic characterization of the natural history of chronic HBV infection revealed by tandem mass tag-based quantitative proteomics approach. *Materials Today Bio*, **2022**, 100302 9.9 0

41 Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection. *Journal of Hepatology*, **2022**, 13.4 0

40 Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection. *Biomedicines*, **2022**, 10, 1224 4.8 0

39 Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment. *World Journal of Gastroenterology*, **2022**, 28, 2251-2281 5.6 2

38 Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion. *Clinical Infectious Diseases*, 11.6 2

37 Mitosis of Hepatitis B virus-infected cells in vitro results in uninfected daughter cells. *JHEP Reports*, **2022**, 100514 10.3 1

36 Platelet-to-Portal Vein Width Ratio and Platelet-to-Spleen Thickness Ratio Can Be Used to Predict Progressive Liver Fibrosis Among Patients With HBV Infection With HBeAg-Negativity and a Normal ALT Level. *Frontiers in Medicine*, 9, 4.9

35 HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC). *BMC Medical Genomics*, **2022**, 15, 3.7

34 Antiviral therapy in hepatitis B virus-infected with immune-tolerant: A meta-analysis. *Gastroenterologia Y Hepatologia*, **2022**, 0.9

33 Capabilities of hepatitis B surface antigen are divergent from hepatitis B virus DNA in delimiting natural history phases of chronic hepatitis B virus infection. *Frontiers in Immunology*, 13, 8.4

32 Mechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies. *Hepatobiliary and Pancreatic Diseases International*, **2022**, 2.1 0

31 Dual role of neddylation in transcription of hepatitis B virus RNAs from cccDNA and production of viral surface antigen. **2022**, 100551

30	HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB.	1
29	Detectability of Hepatitis B Virus in Peripheral Blood Mononuclear Cells Among Naive Chronic Hepatitis B Patients With Negative Viremia. 2022 , 30,	
28	STAT1 is associated with NK cell dysfunction by downregulating NKG2D transcription in chronic HBV-infected patients. 2022 , 227, 152272	0
27	Early initiation of antiviral therapy improves cure of chronic hepatitis B in immune tolerant children: a real-world study.	0
26	Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. 2022 ,	1
25	Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.	2
24	Current treatment of chronic hepatitis B: Clinical aspects and future directions. 13,	0
23	Hepatitis B x (HBx) as a Component of a Functional Cure for Chronic Hepatitis B. 2022 , 10, 2210	1
22	Gut microbiota of hepatitis B virus-infected patients in the immune-tolerant and immune-active phases and their implications in metabolite changes. 2022 , 28, 5188-5202	0
21	Perspectives on current controversial issues in the management of chronic HBV infection.	0
20	Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure. 13,	0
19	Hepatitis Viruses and Hepatoma. 1-7	0
18	Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins. 13,	0
17	Development of a sensitive, multi-assay platform to monitor low levels of HBV DNA and pgRNA in patients with chronic Hepatitis B virus infection. 2022 , 114640	0
16	How to Effectively Monitor Aging Patients with Chronic Hepatitis B: A Review. Volume 17, 1811-1820	0
15	Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells. 2022 , 100664	0
14	The long-term prognosis and the need for histologic assessment in chronic hepatitis B in serological immune-tolerant phase.	0
13	William (Bill) S. Mason.	0

12	Histologic changes in immune-tolerant patients with chronic hepatitis B: a systematic review and meta-analysis. 2023 , 13,	0
11	New Approaches to Chronic Hepatitis B. 2023 , 388, 55-69	1
10	Therapies against chronic hepatitis B infections: The times they are a-changin□but the changing is slow!. 2023 , 210, 105515	0
9	Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis. 2023 , 7, e0011-e0011	0
8	Hepatitis B Virus DNA Integration Drives Carcinogenesis and Provides a New Biomarker for HBV-related HCC. 2023 ,	1
7	A Case Analysis and Literature Review of Combined Hepatocellular-Cholangiocarcinoma after Operation. 2023 , 13, 824-830	0
6	The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?. 2023 , 7, e0060-e0060	0
5	Hepatitis B: epidemiology, natural history, and diagnosis. 2023 , 183-203	0
4	Modification of clinical indicators for differentiating stages of chronic HBV infection based on pathological changes in liver tissue.	0
3	Visualizing in situ viral replication across the natural history of chronic HBV infection. 2023 , 7,	0
2	Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B. 2023 , 15, 997	0
1	HBV Infection and Host Interactions: The Role in Viral Persistence and Oncogenesis. 2023 , 24, 7651	0